Multisystemic manifestations in a cohort of 75 classical Ehlers-Danlos syndrome patients: natural history and nosological perspectives

Marco Ritelli¹, Marina Venturini², Valeria Cinquina¹, Nicola Chiarelli¹ and Marina Colombi¹*

Abstract

Background: The Ehlers-Danlos syndromes (EDS) are rare connective tissue disorders consisting of 13 subtypes with overlapping features including joint hypermobility, skin and generalized connective tissue fragility. Classical EDS (cEDS) is principally caused by heterozygous COL5A1 or COL5A2 variants and rarely by the COL1A1 p.(Arg312Cys) substitution. Current major criteria are (1) skin hyperextensibility plus atrophic scars and (2) generalized joint hypermobility (gJHM). Minor criteria include additional mucocutaneous signs, epicanthal folds, gJHM complications, and an affected first-degree relative. Minimal criteria prompting molecular testing are major criterion 1 plus either major criterion 2 or 3 minor criteria. In addition to these features, the clinical picture also involves multiple organ systems, but large-scale cohort studies are still missing. This study aimed to investigate the multisystemic involvement and natural history of cEDS through a cross-sectional study on a cohort of 75 molecularly confirmed patients evaluated from 2010 to 2019 in a tertiary referral center. The diagnostic criteria, additional mucocutaneous, osteoarticular, musculoskeletal, cardiovascular, gastrointestinal, uro-gynecological, neuropsychiatric, and atopic issues, and facial/ocular features were ascertained, and feature rates compared by sex and age.

Results: Our study confirms that cEDS is mainly characterized by cutaneous and articular involvement, though none of their hallmarks was represented in all cases and suggests a milder multisystemic involvement and a more favorable natural history compared to other EDS subtypes. Abnormal scarring was the most frequent and characteristic sign, skin hyperextensibility and gJHM were less common, all without any sex and age bias; joint instability complications were more recurrent in adults. Some orthopedic features showed a high prevalence, whereas the other issues related to the investigated organ systems were less recurrent with few exceptions and age-related differences.

(Continued on next page)
**Background**

Ehlers–Danlos syndromes (EDS) represent a clinically and genetically heterogeneous group of heritable connective tissue disorders (HCTDs) sharing a variable combination of skin hyperextensibility, joint hypermobility (JHM), and internal organ and vessel fragility. The 2017 international classification of EDS recognizes 13 subtypes that are caused by pathogenic variants in 19 different genes, mainly encoding fibrillar collagens, collagen-modifying proteins, or processing enzymes [1]. The classical (cEDS), vascular (vEDS), and the molecularly unsolved hypermobile (hEDS) EDS subtypes account for more than 90% of patients. cEDS (MIM #130000) has an estimated prevalence of 1/20,000 and it is principally caused by heterozygous pathogenic variants in COL5A1 or COL5A2 encoding type V collagen and rarely by the c.934C>T p.(Arg312Cys) missense variant, spontaneous rupture of large arteries, intracranial aneurysms, and arteriovenous fistulae may occur [5–7, 9–14, 18–26].

A definite diagnosis of cEDS is established by the identification on molecular genetic testing of a heterozygous pathogenic variant in one of the cEDS-associated genes. The largest part of patients carry small COL5A1 pathogenic variants and the majority of these are null alleles (nonsense, frameshift, out-of-frame splice) leading to functional haploinsufficiency; some missense variants, especially within the collagenous domain of the protein, and a few intragenic rearrangements including (multi) exon deletions/duplications are also described [6, 7]. In COL5A2, structural variants (missense, in-frame splice) exerting a dominant negative effect are the most common [4–6, 16]. In patients who fulfill the main clinical features of cEDS, the variant detection rate is about 90% [5, 6]. No clear-cut genotype-phenotype correlations have emerged so far, except that COL5A2 variants seem to result in a more severe phenotype, although numbers are still limited. The EDS Leiden Open Variation Database (LOVD) [27] contains approximately 200 and 60 unique COL5A1 and COL5A2 pathogenic variants, respectively. Until recently, genetic testing was principally based on (serial) single-gene testing by Sanger sequencing, i.e., analysis of COL5A1 is performed first, followed by COL5A2 analysis and then gene-targeted copy number variant analysis to identify large deletions or

**Conclusions:** Our findings define the diagnostic relevance of cutaneous and articular features and additional clinical signs associated to cEDS. Furthermore, our data suggest an update of the current EDS nosology concerning scarring that should be considered separately from skin hyperextensibility and that the clinical diagnosis of cEDS may be enhanced by the accurate evaluation of orthopedic manifestations at all ages, facciocutaneous indicators in children, and some acquired traits related to joint instability complications, premature skin aging, and patterning of abnormal scarring in older individuals.

**Keywords:** Classical Ehlers-Danlos syndrome, Nosology, Atrophic scars, Skin hyperextensibility, Joint hypermobility, Multisystemic involvement, Natural history, COL5A1, COL5A2, COL1A1
duplications. If no pathogenic variant is found, the search for the recurrent COL1A1 p.(Arg312Cys) variant should be performed [1, 6, 16]. As specific types of mutations may be lost due to technical limits, negative molecular testing does not exclude the diagnosis of cEDS; however, alternative diagnosis should be considered mainly if the patient’s phenotype is truly doubtful [1]. Indeed, recognition of cEDS is generally not challenging, since most patients present with the typical cutaneous hallmarks and gJHM (BS ≥ 5/9). However, vast intra- and interfamilial variability tells a much wider clinical presentation [4–6] and an important overlap with other EDS subtypes and HCTDs [1, 9, 16, 28–30]. Nowadays, molecular analysis, especially for doubtful patients, should rely on next generation sequencing (NGS) technologies, including multigene panels containing at least all EDS-associated genes and/or panels comprising genes of the major HCTDs in differential diagnosis and/or a custom phenotype-focused whole exome analysis [1]. Herein, we present a cross-sectional study on a cohort of 75 cEDS patients from 44 families with a confirmed molecular diagnosis focusing on the diagnostic criteria recognized in the current EDS nosology and on additional mucocutaneous, osteoarticular, musculoskeletal, cardiovascular, gastrointestinal, uro-gynecological, neuropsychiatric, atopic, and facial/ocular features, in order to investigate the multisystemic involvement and natural history of the disorder.

Patients and methods

Patients’ cohort and evaluated clinical features

Seventy-five patients, 44 index-cases and 31 relatives, with cEDS were evaluated from 2010 to 2019 in a tertiary referral center for the diagnosis and management of HCTDs (i.e., “Ehlers-Danlos Syndrome and Inherited Connective Tissue Disorders Outpatient Clinic (CESED)” at the Spedali Civili University Hospital of Brescia. Until February 2017, all clinical signs included in the Villefranche nosology [15] were evaluated prior to genetic testing. After the publication of the revised EDS classification, the new criteria were applied for confirmatory molecular analysis and clinical features of the previously evaluated patients were reanalyzed according to the novel guidelines. In addition, several previously diagnosed patients were reevaluated during follow-ups (for number and age at visits see Additional Table 1).

Direct physical examination of available patients systematically consisted in different steps. First, facial features, including frontal and other facial scars, ocular anomalies and other traits, as well as the appearance, location, and number of scars all over the body were searched and documented by clinical photographs (Figs. 1 and 2). Ocular signs included epicanthal folds, palpebral ptosis, sunken eyes, infraorbital creases, hypertelorism, hypertelorism/telecanthus, myopia, strabismus, xerophthalmia, and elongated/up-slanting palpebral fissures (Fig. 2). Additional investigated facial features comprised micro/retrognathia, low-set ears, anteverted nostrils, elongated philtrum, and hypoplasic auricular lobe. Atrophic scars were extremely variable in clinical appearance; in particular, 3 different frequent morphologies were identified and classified as papyraceous, hemosiderotic, and cigarette paper (Fig. 1). Scarring was designed positive only in patients with multiple, widened scars at the typical areas (knees, elbows, forehead, shins, chin, etc.), whereas small, isolated, single, or post-surgical scars were not considered representative of cEDS. Second, to assess texture/consistence, the skin was touched at different sites including arms, thorax, hands and legs. Soft/velvety/doughy skin was an entirely subjective feeling developed during clinical practice. Third, to assess hyperextensibility, the skin was stretched in specific points comprising upper eyelids, neck, dorsum of hand and forearm, chest, abdomen, elbows, and knees. Skin was considered hyperextensible when overextended according to the standardized cut off values in at least 3 of the areas defined in the 2017 EDS nosology [1]. Further evaluated mucocutaneous features included molluscoid pseudotumors, easy bruising, subcutaneous spheroids, inguinal, umbilical, and incisional hernia, keloid formation, gingival inflammation/recession, livedo reticularis, keratosis pilaris/hyperkeratosis of extensor surfaces, xerosis, striae distensae/rubrae, resistance to local anesthetic drugs, acquired cutis laxa/premature skin aging, piezogenic papules of the heels, abnormalities of the uvula, absent/short lingual frenulum, and light blue sclerae. Subsequently, JHM was evaluated according to the BS [15]; in adults with a BS < 5 the presence of historical JHM was routinely investigated with the five-point questionnaire [31].

In addition, we selected a set of clinical features and signs related to almost all organ systems by adapting our clinical checklist routinely used for the assessment of patients with a suspicion of hEDS, in which the multisystemic involvement is already well recognized, even though not codified yet in the current nosology [1]. Further assessed musculoskeletal and orthopedic features included congenital hip dysplasia, sprains, (fixed) dislocations, subdislocations, articular pain, back pain, recurrent inflammatory soft-tissue lesions (i.e., bursitis, tendinitis, myofascial pain, carpal tunnel syndrome, epicondylitis, tenosynovitis, plantar fasciitis), walking difficulties, limited walking autonomy, temporomandibular joint dysfunction, high arched/narrow palate, marfanoid habitus (arm span to height ratio > 1.05), arachnodactyly (positive thumb/wrist sign), (non-surgical) pectus exca vatum/carina tum, scoliosis, dorsal hyperkyphosis, cervical spine curvature anomalies, lumbar hyperlordosis/
hypolordosis, minor asymmetry at lower limbs (anatomical or functional anisomelia) or other body areas, cubita/genua valga, halluces valgi, and pes planus/cavus. When available, the documented presence of disc hernias/protrusions, osteopenia/osteoporosis, and spondylolisthesis was recorded. In patients with osteopenia/osteoporosis the main primary causes (e.g. hormonal and vitamin D deficiencies, lifestyle, and medications) were investigated. Cardiovascular features that were systematically explored included varicose veins, Raynaud’s phenomenon, acrocyanosis, livedo reticularis, capillary fragility, and recurrent epistaxis or gingival bleeding. When possible, the presence of arterial aneurysms, progressive aortic root dilatation, aortic ectasia, valvular regurgitation with hemodynamic involvement, and mitral valve prolapse (MVP) was investigated by cerebral, thoracic, abdominal magnetic resonance imaging (MRI) and/or heart ultrasound. In patients with extensive easy bruising, routine coagulation tests were performed resulting normal in all. Assessed muscular features included hypotonia at birth, muscle hypotonia, recurrent myalgias and cramps, involuntary muscle contractions, and fibromyalgia. Investigated gastrointestinal features comprised gastroesophageal reflux, dysphagia, hialtal hernia, food intolerances, celiac disease, abdominal pain, defecatory dysfunction, delayed gastric/bowel/colonic transit, dolicho-colon, and visceroptosis. Investigated uro-gynecological features included disabling dysmenorrhea, meno/metrorrhagia, post-partum hemorrhage, urinary stress incontinence, cervical insufficiency during pregnancy, and rectal or pelvic prolapse. Assessed neuropsychiatric features were delayed motor development, clumsiness, chronic

**Fig. 1 A**) Representative images of different atrophic scars on cEDS patients’ knees. A healing scar in a 6-year-old girl (**a**); a papyraceous, non-hemosiderotic scar in a 22-year-old female (**b**); a cigarette paper scar in a 39-year-old female (**c**); multiple papyraceous, hemosiderotic scars in a 40-year-old female (**d**); multiple papyraceous scars in a 57-year-old male (**e**); combination of multiple, papyraceous, hemosiderotic scars, and cigarette paper scars in a 34-year-old female (**f**). **B**) Evolution of papyraceous, and hemosiderotic scars in 2 children assessed at increasing ages. On the left, a single scar on the knee and multiple scars at the pretibial area in a girl at 6 (**a, b**) and 11 years of age (**c, d**); on the right, multiple scars on the knee in a boy at 9 (**e**) and 12 years of age (**f**).
fatigue, headache/migraine, impaired memory and concentration, paresthesia, cardiovascular dysautonomia, sleep disturbances, anxiety/panic/fears, allodynia, depression, and neuropathic pain. Immunological features included allergy/atopy, rhinitis/rhinoconjunctivitis, asthma, and atopic dermatitis.

Assessment between the presence/absence of investigated features and selected dichotomous variables, i.e., age at last examination < or ≥ 18 years and gender, was performed with the chi-square test with Yates’s correction or Fisher’s exact test whenever the count was insufficient. Analysis was carried out with the GraphPad Software and considering significant p-values when less than 0.05. In patients who have been evaluated at more than one visit, the 2017 diagnostic criteria were analyzed at the different ages, in order to appraise if they changed over time.

Genetic testing
Molecular analysis was performed on genomic DNA purified from peripheral blood leukocytes by standard procedures. Most patients were characterized according to our previously reported molecular flow-chart based on (serial) single-gene Sanger sequencing [6]. In particular, all exons and intron-flanking regions of COL5A1 (NM_000093.3, NP_000084.3), COL5A2 (NM_000393.5, NP_000384.2), and exon 14 of COL1A1 (NM_000088.4, NP_000079.2) were amplified by PCR with optimized primer sets (available upon request) followed by bidirectional Sanger sequencing with the BigDye Terminator v1.1 Cycle Sequencing kit on an ABI3130XL Genetic Analyzer (Life Technologies). Sequences were analyzed with the Sequencher 5.1 software (www.genecodes.com) and variants annotated by using the Alamut Visual software version 2.15 (Interactive Biosoftware, Sophia Genetics). Since 2018, massive parallel sequencing methods were applied in our laboratory and positive results confirmed by Sanger sequencing. For this study, patients were characterized by using an in-house NGS panel including all cEDS-associated genes. Briefly, two panel pools of the custom “connective tissue panel”, CTP (COL5A1, COL5A2, COL1A1, COL1A2, COL3A1,
B3GALT6, B4GALT7, SLC39A13, FKBP14, ADAMTS2, CHST14, DSE, FLNA, ACTA2, MYH11, MYLK, NOTCH1, MFAP5, PRKG1, SLC2A10, TGFB1, TGFB2, SMAD2, SMAD3, SMAD4, TGFB2, TGFBR3, FBN1) were generated with the AmpliSeq library kit 2.0, which includes reagents for generating amplicons with the Ion AmpliSeq primers and the Ion Xpress™ Barcode Adapters, following manufacturer’s protocols (Thermo Fisher Scientific). Library template preparation was performed with the Ion 520 & Ion 530 kit – OT2 on the Ion OneTouch 2 instrument starting from a pool of 15 barcoded libraries (8 μl of 100 pM pooled library) and sequenced on the Ion S5 instrument with the Ion 520 chip. Baseline and sequence alignment against hg19 genome assembly were performed with the Ion Torrent Suite software v.5.0.2 and genetic variants were identified by the Ion Torrent Variant Caller v.5.0.2.1. Further analyses were performed with the Ion Reporter software 5.6. In patients without a pathogenic variant, deletion/duplication analysis was performed through Multiplex Ligation-dependent Probe Amplification (MLPA) analysis with the SALSA MLPA P331 and P332 Probe Mixes, according to manufacturer’s instructions (MRCHolland). All novel pathogenic variants were submitted to the EDS LOVD [27].

Results

General and molecular findings

Among the 75 cEDS patients from 44 families described here, 45 were females (60%) and 30 were males (40%) (sex ratio: 1.5). By considering the index-cases, the sex ratio was 1.75 (28 females and 16 males). Forty-nine patients from 31 families were previously published in [6]. The sex ratio was 1.5. Among 49 earlier published patients that were included in the present study, 24 were reassessed at least once during scheduled follow-up visits (Additional Table 1). Age at last examination ranged from 3 to 67 years (mean 27; standard deviation [SD] 18.3). In particular, age range was 3 to 67 (mean 27.2; SD 17.8) for females, and 3 to 63 (mean 29.7; SD 19) for males. Patients younger than 18 years old were 31 (41.3%) and 44 (58.7%) patients were adults (≥18 years). In all new families, a COL5A1 pathogenic variant was identified mainly by using the NGS CTP and submitted to the EDS LOVD. In particular, we disclosed a previously reported nonsense mutation [6] and 10 novel variants, i.e., 2 nonsense, 3 small deletions, and 1 multi-exon deletion, all predicted leading to haploinsufficiency, and 2 in-frame exon skipping splice variants, 1 glycine substitution, and 1 intermediate-sized duplication (63 bp) within the collagenous domain of the protein and with an estimated dominant negative effect. Detailed clinical and molecular features by single patient and the corresponding LOVD IDs are reported in Additional Table 1. Frequencies of selected clinical features are reported in Table 1, in Figs. 3 and 4, and in Additional Table 2.

Diagnostic criteria according to the 2017 EDS nosology and additional mucocutaneous, osteoarticular, and facial/ocular features

The two major criteria for cEDS, namely marked skin hyperextensibility plus extensive, widened atrophic scar- ring and gHM, were present respectively in 78.7% and 58.7% of patients at last evaluation without any correlation with sex and age (Table 1). Among minor criteria, skin fragility (89.3%), easy bruising (86.7%), and soft doughy skin (78.7%) were the most frequent cutaneous signs; molluscoid pseudotumors (29.3%) and spheroids (27.6%) were less common. These features did not show any significant difference between sex and age categories, whereas hernias and epicanthal folds (Fig. 2A) were more frequent in young patients (58.1% vs 20.5 and 32.3% vs 9.1%, respectively). At least one gHM complication was present in 93.3% of patients, with bilateral pes planus (82.7%) as the most common feature without any correlation with sex and age. A higher prevalence in adults compared to younger individuals was clearly evident for the occurrence of sprains, especially of heels, fingers/wrist, and knees (59.1% vs 25.8%), joint and limb pain (61.4% vs 9.7%), and dislocations (34.1% vs 3.2%) that involved primarily shoulder, digits, hip, radius, and clavicles (Additional Table 1). Subdislocations were also more common in adults (36.4% vs 19.4%), although not statistically significant. Two or more of gHM complications were present especially in adults (73.8% vs 35.7%). Fixed dislocations, particularly of shoulders, were sporadic events (6.7%). Likewise, chronic disabling pain was infrequent and patients, mainly adults, used principally nonsteroidal anti-inflammatory drugs or paracetamol on demand, whereas opioid therapy was very uncommon (Additional Table 2). Finally, the last minor criterion, namely family history of a first-degree relative meeting clinical criteria, was more common in adults (72.7% vs 32.3%).

Minimal criteria for a cEDS suspicion were present in 59/75 (78.7%) of patients; 49.3% showed both major cri- teria while 29.3% major criterion 1 together with at least three minor criteria; both combinations did not show sex- and age-related differences. Overall, 16/75 patients (21.3%) of our cohort did not fulfill the combined major criterion 1, i.e., 10 for the absence of generalized skin hyperextensibility, 1 for the lack of typical scarring, and 5 for the absence of both features (Additional Table 1).
Localized skin hyperextensibility (less than 3 sites) was present in 9/75 patients and the complete absence of skin hyperextensibility in 6/75 (Additional Table 2). Concerning skin fragility, 92% of patients (69/75) showed extensive, widened atrophic scars and the most frequent types were papyraceous (65.3%), hemosiderotic (54.7%), and cigarette paper (40%) (Fig. 1A). The rate of hemosiderotic scars was significantly higher in young patients compared to adults (Additional Table 2). Further frequent (> 30%) mucocutaneous features were piezogenic papules of the heels (86.7%), light blue sclerae (58.7%), uvalar abnormalities (44.1%), acquired cutis laxa/premature skin aging (41.3%), striae distensae/rubrae (40%), and keratosis pilaris/hyperkeratosis of extensor surfaces (30.7%). Among these, light blue sclerae were more common in young females, while acquired cutis laxa, premature skin aging, and striae distensae/rubrae were more recurring in adults, with the latter more frequent in females (Fig. 3a and Additional Table 2).

Further recognized osteoarticular features were recurrent inflammatory soft-tissue lesions (33.8%), more frequently observed in adults (48.8% vs 12.9%), and temporomandibular joint dysfunctions (28.8%). Walking difficulties (22.7%) and limited walking autonomy (10.7%) were rare and occurred more repeatedly in adults, though not statistically significant. Mobile patellae were present in 6/75 patients (8%). Congenital hip dysplasia was encountered only in 2 patients as well as spontaneous Achilles tendon rupture (Fig. 3b and Additional Tables 1 and 2).

Apart from epicanthal folds, additional midface/ocular signs were palpebral ptosis and sunken eyes (both 32%) and infraorbital creases (29.3%) (Fig. 2). Myopia (25.3%) was more common in adults. The other non-ocular facial features were mostly sporadic observations, except for micro-retrogнатhia (29.3%) and hypoplastic auricular lobe (20%), the latter with a predominance in young patients (Fig. 3c and Additional Table 2).

### Table 1 Major, minor, and minimal criteria according to the 2017 nosology of classical Ehlers-Danlos syndrome

|                           | Total          | Males          | Females        | p-value<sup>A</sup> | Patients < 18 | Patients ≥ 18 | p-value<sup>B</sup> |
|---------------------------|----------------|----------------|----------------|--------------------|---------------|---------------|--------------------|
|                           | N/T %          | N/T %          | N/T %          |                    | N/T %         | N/T %         |                    |
| **Major Criteria**        |                |                |                |                    |               |               |                    |
| Generalized skin hyperextensibility plus extensive atrophic scarring | 59/75 78.67 | 26/30 86.66 | 33/45 73.33 | .274 | 24/31 77.41 | 35/44 79.54 | .948 |
| Generalized joint hypermobility (BS ≥ 5) | 44/75 58.66 | 14/30 46.66 | 30/45 66.66 | .138 | 19/31 61.29 | 25/44 56.81 | .881 |
| **Minor Criteria**        |                |                |                |                    |               |               |                    |
| Easy bruising             | 65/75 86.66   | 25/30 83.33   | 40/45 88.88   | .728 | 29/31 93.54 | 36/44 81.81 | .181 |
| Soft, doughy skin         | 59/75 78.66   | 24/30 80.00   | 35/45 77.77   | .954 | 24/31 77.41 | 35/44 79.54 | .948 |
| Skin fragility (or traumatic splitting) | 67/75 89.33 | 28/30 93.33 | 39/45 86.66 | .593 | 30/31 96.77 | 37/44 84.09 | .129 |
| Molluscoid pseudotumors   | 22/75 29.33   | 13/30 43.33   | 9/45 20.00    | .055 | 10/31 32.25 | 12/44 27.27 | .834 |
| Subcutaneous spheroids    | 18/65 27.60   | 7/24 29.17    | 11/41 26.83   | .623 | 10/29 34.48 | 8/36 22.22 | .412 |
| Inguinal/umbilical/incisional hernia | 27/75 36.00 | 10/30 33.33 | 17/45 37.78 | .883 | 18/31 58.06 | 9/44 20.45 | .002 |
| Epicantal folds           | 14/75 18.66   | 6/30 20.00    | 8/45 17.77    | .951 | 10/31 32.25 | 4/44 9.09 | .025 |
| Complications of joint hypermobility (at least 1) | 70/75 93.33 | 28/30 93.33 | 42/45 93.33 | .636 | 28/31 90.32 | 42/44 95.45 | .683 |
| Bilateral pes planus      | 62/75 82.66   | 25/30 83.33   | 37/45 82.22   | .851 | 27/31 87.09 | 35/44 79.54 | .588 |
| Sprains                   | 34/75 45.33   | 17/30 56.66   | 17/45 37.77   | .169 | 8/31 25.80 | 26/44 59.09 | .008 |
| Pain                      | 30/75 40.00   | 12/30 40.00   | 18/45 40.00   | .809 | 3/31 9.67 | 27/44 61.36 | .001 |
| Subdislocations           | 22/75 29.33   | 8/30 26.66    | 14/45 31.11   | .876 | 6/31 19.35 | 16/44 36.36 | .181 |
| Dislocations              | 16/75 21.33   | 9/30 30.00    | 7/45 15.55    | .226 | 1/31 3.22 | 15/44 34.09 | .001 |
| Two or more of these complications | 41/70 58.57 | 19/28 67.85 | 22/42 52.38 | .298 | 10/28 35.71 | 31/42 73.80 | .003 |
| **Family history of a first degree relative who meets clinical criteria** | 42/75 56.00 | 17/30 56.66 | 25/45 55.55 | .886 | 10/31 32.25 | 32/44 72.72 | .001 |
| **Minimal Criteria**      |                |                |                |                    |                |                |                    |
| Major criterion 1 plus major criterion 2 | 37/75 49.33 | 13/30 43.33 | 24/45 53.33 | .540 | 14/24 58.33 | 23/44 52.27 | .822 |
| Major criterion 1 plus at least 3 minor criteria | 22/75 29.33 | 13/30 43.33 | 9/45 20.00 | .055 | 10/24 41.566 | 12/44 27.27 | .963 |

**Abbreviations:** N number of patients presenting the investigated feature, T total number of patients in whom the feature was investigated

Significant p-values < 0.05 are in bold

A: p-values females vs males
B: p-values patients < 18 years vs patients ≥ 18 years
Considering that we reassessed 24 patients during follow-up (approximately 2–5 years after first examination), we had the possibility to evaluate if the major, minor, and minimal criteria changed over time in an individual single patient. Though the limited time period of observation (range 2–7 years), gJHM displayed an age influence. Indeed, in 14/24 patients (8 males and 6 females) a decrease of the BS was observed, and at last examination 5 of these patients (all males) displayed a BS < 5, hence not fulfilling the major criterion 2. The most striking difference was observed in a boy who showed at 10 years of age a BS of 9/9 that 4 years later changed to 2/9. Additional differences included a female that 7 years after the first assessment showed subcutaneous spheroids, and 2 patients (1 female and 1 male) who displayed after 4 years the presence of multiple molluscoid pseudotumors (Additional Table 1). While we did not observe any striking difference concerning skin hyperextensibility as well as the other minor criteria, in most patients, especially in adolescence, scars changed over time both in dimension and appearance. For instance, if no further injury occurred at the same area, large, thickened, raised, papyraceous, and hemosiderotic scars usually tended to resolve in smaller, flatter, and less hemosiderotic or even in cigarette paper scars (Fig. 1B).

Orthopedic features

In almost all patients of our cohort we systematically evaluated 15 orthopedic features (Fig. 3d and Additional Table 2). The most recurrent (≥ 50%) were minor asymmetry at lower limbs or at other body areas (83.6%), mild scoliosis (74.3%), lumbar hyperlordosis/hypolordosis (57.9%), cubita/genua valga or halluces valgi (53.3%), and high arched/narrow palate (50%); all these features did not show any apparent sex and age bias. Osteopenia (T-scores between −1.0 and −2.4) was identified in 11 (8 females and 3 males) out 21 investigated adults (35.5%), whereas it was absent in 10 examined young individuals. The age range of patients with osteopenia was 29 to 58 (mean 41.5, SD 9.3). Osteoporosis (T-scores above −2.5) was diagnosed only in 5/21 adults (16.1%, 4 females and 1 male, mean age 38.6, SD 11.4). Vitamin D deficiency was found in 4 patients and cholecalciferol treatment was commenced. Dorsal hyperkyphosis was present in 27.5% of patients without any sex- and age-related difference. A similar frequency was identified also for cervical spine curvature anomalies, but with a higher rate in adults compared to individuals aged below 18 years (36.5% vs 11.1%). Back pain (56.8% vs 12.9%), disk hernias/protrusions (27.9% vs 3.4%), and spondylolisthesis...
(2.5% vs 0%) were all more common in adults. Finally, non-surgical pectus excavatum/carinatum showed a higher prevalence in males compared to females (40% vs 11.1%) and in 1 of them marfanoid habitus and arachnodactyly were also evident. Other rare findings comprised short stature, dental malocclusion, radiological vertebral fractures, surgically treated congenital kyphoscoliosis, winged scapulae, ulnar deviation, brachydactyly, hypoplasia of the upper femur, arthrosis, osteoarthritis, club feet, pes cavus, and hindfoot deformities (Additional Table 1).

Cardiovascular features
Apart from easy bruising, the most commonly observed cardiovascular sign in our cohort was MVP (42.4%), which was especially recognized in adults (56.4% vs 22.2), followed by capillary fragility/recurrent epistaxis/gingival bleeding (41.3%), valvular regurgitation with mild hemodynamic involvement (34.8%), varicose veins (20%), and Raynaud’s phenomenon/acrocyanosis/livedo reticularis (10.6%), all without any significant difference between sex and age categories, with the exception of varicose veins that were more frequent in adults. Non-progressive aortic root dilatation (9.1%) was detected only in adults, namely in 5/27 investigated males and in 1/39 females; as well as aortic ectasia (z score > 2) that was documented in 2 adult males, one patient carried the COLIA1 c.934C>T p.(Arg312Cys) missense variant and the other a COL5A1 null allele (Additional Tables 1 and 2, Fig. 4a). Spontaneous rupture of large arteries did not occur in our cohort. Additional sporadic findings included posterior cerebral artery hypoplasia, intracranial aneurysm, vertebral artery tortuosity, atrioventricular block, tricuspid valve prolapse, interatrial septal aneurysm, bicuspid aortic valve, delayed right ventricular conduction, left ventricular thickening, ventricular arrhythmia, tachycardia with extrasystoles, arteriovenous fistula, and deep venous thrombosis (Additional Table 1).

Muscular features
Among the 5 investigated muscular signs (Additional Table 1 and Fig. 4b), the most common issues were recurrent myalgias and cramps (41.3%) that affected mainly adults (52.3% vs 25.8%). Hypotonia at birth was infrequent (14.7%) as well as muscle hypotonia of mild degree (6.7%) and involuntary muscle contractions (5.3%). Confirmed fibromyalgia was present only in 1 patient with the most severe form of cEDS, carrying a structural mutation in COL5A2 (Patient 14 in Additional Table 1), who also suffered from recurrent muscle hematomas and ruptures.
Gastrointestinal features
In almost all individuals of our cohort we assessed 11 gastrointestinal features (Additional Table 2 and Fig. 4c). The most recurrent problem, especially in adults, was gastroesophageal reflex (52.3% vs 22.6%). Treatment with proton pump inhibitors was resolutive in most cases, only 3 patients required fundoplication (Additional Table 1). Defecatory dysfunction (33.3%), delayed gastric/bowel/colonic transit (26.3%), various food intolerances, unexplained abdominal pain (both 16%), and dysphagia were less common and did not show any sex and age bias. Sporadic findings comprised hiatal hernia, visceroptosis (gastroptosis, enteroptosis), dolichocolon, confirmed celiac disease, and gastric ulcer (Additional Table 2). Inflammatory bowel disease was not recognized. In one patient a postnatal intestinal perforation with meconium peritonitis requiring ileostomy occurred.

Uro-gynecological features
Among females in reproductive age (26 adults and 5 aged below 18 years), disabling dysmenorrhea (22.6%) and meno/metrorrhagias (16.1%) were the most frequent gynecological issues (Additional Table 2 and Fig. 4d). One patient suffered from amenorrhea since the age of 24 (Patient 11 in Additional Table 1). Twenty out of 31 women had at least one pregnancy and 8 of them had multiple pregnancies. Fourteen of the children were affected. Multiple miscarriages occurred in 4 patients. Post-partum uterine hemorrhage and a third-degree vaginal laceration during delivery occurred in 2 and 1 patients, respectively. Premature rupture of membranes with preterm delivery was present in 1 patient with an affected fetus; 16 women had uncomplicated pregnancies and delivery (Additional Table 1).

In the entire patients’ cohort, urinary stress incontinence was very rare (2.7%). In the most severely affected patient (Patient 14), both rectal and urethral prolapse together with recurrent hemorrhagic cystitis occurred. Further occasional issues were microhematuria, urinary retention, testicular cysts, bilateral mobile testis, pelvic varicoceles, cryptorchidism, and bladder diverticula and hypoplasia (Additional Table 1).

Neuropsychiatric features
In order to explore the neurological, psychological and emotional dysfunctions in cEDS, we investigated 12 features (Additional Table 2 and Fig. 4e). The most common problematic was headache/migraine, which was reported by 41.3% of patients without significant sex- and age-related differences, even if it affected more frequently adult females. Motor clumsiness was reported by 36.5% of patients as well as chronic fatigue (36%), the latter was more frequent in adults (45.5% vs 22.6%), although not statistically significant. Abnormal sensation of the skin (e.g. formication, tingling, pricking, chilling, burning, and numbness) was described by 25.3% of patients, especially by adults (36.4% vs 9.7%). Paresthesia was most commonly occurring in arms, legs, and abdomen and was usually painless and transient, except for 5 females who mentioned chronic formication (Additional Table 1). A documented cardiovascular dysautonomia was present in 16% of patients, particularly in adult females, although not reaching a statistic significance. The most recurrent symptom was orthostatic intolerance and in 9 patients tilt-table testing resulted positive. Further associated symptoms were mood swings, fatigue, problems with concentration and memory, gastrointestinal complications, anxiety/panic/fears, and sleep disturbance (Additional Table 1). These latter issues were both reported also by patients without cardiovascular dysautonomia with an overall frequency of 14.7% without any sex and age bias. Allodynia (13.5%) was more recurrent in adults (20.5% vs 3.3%). The occurrence of either mechanical (especially static), thermal (hot and cold), or movement (joints and/or muscles) allodynia was referred. Delayed motor development, usually associated with primary hypotonia (Additional Table 1), was present in 10.7% of patients without any significant variance between sex and age categories. Chronic depression requiring pharmacological treatment was diagnosed in 3 patients (1 adult female and 2 adolescents), one of the latter showed a self-injurious behavior and attempted suicide (Additional Table 1). Chronic neuropathic pain was present only in the most severely affected patient (Patient 14). Further sporadic features were epileptic seizures (2 patients from the same family), mild hearing loss, absence of sphincter control, and developmental coordination disorder affecting fine and gross motor skills (Additional Table 1).

Atopic features
In the entire cohort, immunological issues were quite rare (Additional Table 2 and Fig. 4f). Allergy/atopy (32%) was the most recurrent problem followed by recurrent rhinitis/rhinoconjunctivitis (14.7%) and confirmed atopic dermatitis (10.7%). Asthma afflicted only 3 out of 75 patients. The most common allergens were various foods, pollen, animal dander (especially cat hair), and dust mites. Treatment with corticosteroids was resolutive in almost all patients and anaphylaxis did never occur. One patient suffered from chronic sinusitis (Additional Table 1).

Discussion
This study on a cohort of 75 molecularly proven cEDS patients aimed to validate the revised diagnostic criteria and explore the multisystemic involvement of the disorder by comparing types and incidences of the
numerous clinical manifestations at different ages and with those observed in other EDS subtypes, in order to delineate natural history and assist differential diagnosis. Our results confirm the notion that cEDS is basically characterized by cutaneous and articular involvement, even though none of their hallmarks is represented in 100% of cases, and show that osteoarticular and musculoskeletal complaints as well as gastrointestinal, uro-gynecological, neuropsychiatric, and cardiovascular associated symptoms (and disorders) are not so prominent compared to other EDS subtypes.

Albeit the cEDS-specific triad, i.e., widened, atrophic scars (92% of patients and ~ 95% of probands), marked skin hyperextensibility (80% of patients and ~ 82% of probands), and gJHM (BS ≥5, ~ 59% of patients and ~ 66% of probands), is highly predictive for molecular confirmation of the diagnosis, this combination was observed only in ~ 49% of patients and in ~ 55% of probands. Hence, the suspect of cEDS is not always driven by the traditional criteria but is rather gestaltic and based on the overall clinical presentation. Our findings offer future perspectives for a revision of the EDS nosology in terms of diagnostic criteria. The observation that in our cohort only ~ 79% of patients and ~ 82% of probands fulfilled the currently defined minimal criteria for a suspicion of the disease, which require the presence of the combined major criterion 1, indicates that their strict application could lead to a lack of diagnoses. Hence, we recommend that atrophic scarring should be considered independently from skin hyperextensibility as an alone-standing major criterion 1. We also propose that minimal criteria prompting genetic testing should be typical cEDS scars (at more than 2 sites) plus either generalized skin hyperextensibility (at least 3 of the currently defined areas and according to their cut-off values) and/or gJHM (BS ≥5), and/or 3 of the currently defined minor criteria, to which orthopedic issues may be added. In view of intrafamilial variability, a family history with a documented pathogenic variant is sufficient for genetic testing in individuals not fulfilling the criteria.

These suggestions are supported first by the fact that in our sample abnormal scarring was undoubtedly the most common sign. Although scarring was variable in clinical appearance and affected sites and is shared by other EDS subtypes and HCTDs [1, 9, 28–30, 32–35], scars should basically be considered representative of cEDS. Indeed, in our cohort, scars were typically numerous, large, papyraceous, and hemosiderotic. The findings that the rate of hemosiderotic scars was significantly higher in young patients and that adults often presented small and flat scars suggest an evolving phenotype and natural history of scarring that usually becomes less severe in adulthood (Fig. 1) and is likely influenced by patients’ habits. Defective scarring in cEDS is always secondary to soft tissue traumas, which occur more likely in childhood in exposed areas such as forehead, knees, and elbows, and in those near the underlying bones (e.g., pretibial region), due to skin fragility joined with a defective wound healing. The reevaluation of scars in single individuals over time (Fig. 1) corroborates the concept of an evolving phenotype and suggests that once a cEDS diagnosis is made (or in the presence of a positive family history) and management guidelines for prevention of primary manifestations are provided (e.g., avoiding contact sports or wearing protective pads or bandages over forehead, knees, and shins during activities), scarring generally becomes less significant, except for severe cases.

The proposal to modify the current diagnostic criteria also derives from the observation that in 15 out of 16 patients of our cohort who did not satisfy the major criterion 1 (and consequently neither the minimal criteria for genetic testing), this was due to the absence of generalized skin hyperextensibility. Ten of these patients showed the typical cEDS scars and 5 of them also had an affected family member fulfilling the criteria, thus prompting molecular analysis. Likewise, among the 5 patients who did not show both features of criterion 1, 3 had a first-degree parent meeting the criteria and one an affected mother with positive skin hyperextensibility, although without the typical cEDS scars [8]. The most uncertain patient was a sporadic female (Patient 23 in Additional Table 1) who presented only a single, small atrophic scar and localized skin hyperextensibility at elbows and knees. In addition to this latter sign, the presence of gJHM and its complications and further minor signs prompted molecular analysis that revealed a pathogenic COL5A1 variant. This case highpoints that while molecular diagnosis in patients with a full-blown phenotype is mainly confirmatory, in those with an incomplete presentation it turns out to be fundamental, since these individuals might not be diagnosed or even be misdiagnosed. Indeed, considering the clinical overlap not only between the different EDS subtypes but also with other HCTDs [1, 9, 28, 30, 32, 35–49], differential diagnosis is not always forthright. Differential diagnosis includes the molecularly unsolved hEDS that shares with cEDS gJHM and more than a few (muco) cutaneous signs; however, hEDS patients usually show a lower degree of scarring and skin hyperextensibility and much more striking gJHM complications [1, 7, 28, 29, 50]. Molluscoid pseudotumors and subcutaneous spheroids are highly diagnostic of cEDS, even if they were rarely observed in our patients’ cohort. Signs of premature skin aging, including acquired cutis laxa of the extremities and skin wrinkling, although less specific, might also help in the differential with hEDS, especially in adults. The additional
mucocutaneous features, including abnormal skin texture, easy bruising, hernias, piezogenic papules, light blue sclerae, uvular abnormalities, striae distensae/rubrae, keratosis pilaris/hyperkeratosis of extensor surfaces, absent/short lingual frenulum, resistance to local anesthetic drugs, and gingival inflammation/recession, are almost all shared not only with hEDS but also with other EDS subtypes and HCTDs [28, 29]. As such, the recording of these features at physical examination might reinforce the suspect of systemic disorder, but their low specificity does not attend for confirmatory genetic testing. In cases compatible with an autosomal recessive transmission, differential diagnosis includes the rare classical-like EDS (cEDS) type 1, a.k.a. TNXB deficiency [51], and the recently defined cEDS type 2 caused by biallelic variants in AEBP1 [52]. The cEDS type 1 is generally distinguishable from cEDS for the absence of atrophic scarring [28, 45, 53–57], whereas a more severe multisystemic presentation in cEDS type 2 should assist the differential diagnosis with cEDS [43, 52, 58–60].

The dermatosparaxis (ADAMTS2) [61], cardiac-valvular (COL1A2) [62–64], kyphoscoliotic (PLOD1, FKBP14) [65, 66], and arthrochalasia (COLIA1, COLIA2) [67, 68] EDS subtypes, also sharing with cEDS several cutaneous and articular issues, are mostly distinguishable for the presence of specific hallmarks [1, 9, 16]. Concerning the other major criterion of cEDS, gJHM remains undeniably characteristic of the disorder, even if in our sample a BS ≥ 5 was identified in less than 60% of patients and it is common to all EDS subtypes and other HCTDs [1, 9, 28, 30, 36–39, 47, 50, 69, 70]. In our previously published smaller cEDS cohort [7], a lower incidence of gJHM was observed in adults compared to younger individuals, suggesting that age affects JHM also in cEDS, as more widely demonstrated in hEDS and in which an age-dependent BS was introduced in the revised diagnostic criteria [1, 50, 69, 71–73]. In the present larger cEDS cohort, no statistically significant difference emerged between age at ascertainment and BS ≥ 5 (~ 57% in adults vs ~ 61% in young individuals), suggesting a different natural history of JHM compared to hEDS. Indeed, although patients’ reassessment at different ages showed a decrease of the BS in 12/24 investigated patients, only in 5 males it resulted below the cut-off value of 5/9. A different age influence and disease course in cEDS seems to occur also for joint instability complications, such as dislocations, sprains, and soft-tissue injuries. In hEDS, it was previously shown that there were no overt associations between age and their frequency and location, except for soft-tissue injuries that exhibited a higher rate in adults [73]. In our cEDS patients’ cohort, these gJHM complications as well as articular pain, which in general was of mild degree, were instead all more frequently observed in adulthood. However, gJHM complications showed an overall lower rate with the exclusion of pes planus (present in most patients) and recurrent inflammatory soft-tissue injuries, among which plantar fasciitis, bursitis, and tenosynovitis were particularly frequent. Furthermore, dislocations usually resolved spontaneously and were in general easily managed by the affected individual. Hence, in cEDS, a BS ≥ 5 and mild to moderate joint instability complications seem valid markers in adults, especially in those with a minor or naturally diminished cutaneous phenotype (Fig. 1). In contrast, gJHM and its related issues might lack both sensitivity and specificity in children, in whom, however, the typical cutaneous hallmark is nearly always plainly manifest. Furthermore, the presence of epicanthal folds and/or infraorbital creases or an association of the other eye findings and/or non-ocular features plus abnormal facial scars seems to denote a further distinctive gestaltic presentation of young cEDS patients, which usually attenuates or even vanishes over the years (Fig. 2).

Musculoskeletal involvement was an interesting finding in our cohort, due to the high prevalence of some related issues, thus suggesting that the registration of these features might strengthen the suspect of cEDS, although with a low specificity. This is particularly true for orthopedic features, considering that in our cohort minor asymmetry at lower limbs and/or other body areas, scoliotic attitude/mild scoliosis, lumbar hyperlordosis/hypolordosis, valgus deformities of elbows, knees, and feet, and high arched/narrow palate were all observed with a frequency above 50% without any sex and age bias. Hence, it is reasonable to propose that the presence of 3 or more of these issues might be considered as an additional minor criterion in a future nosology revision. Osteopenia and osteoporosis, dorsal hyperkyphosis, cervical spine curvature anomalies, pectus deformities, disk hernias/protrusions, and spondylolisthesis as well as severe back pain (≥ 7 NRS numeric pain rating scale), which in general associated with the presence of radiological vertebral fractures (Additional Table 1), were less frequent but all more recurrent in adults, except for dorsal hyperkyphosis and pectus anomalies. Osteoarthritis, which has been postulated as a long-term consequence of JHM and related altered joint biomechanics [69], was instead only a sporadic finding in our cEDS cohort as well as marfanoid habitus. Our results partly support the still controversial impression that bone quality might be impaired in cEDS [74–78], although undoubtfully less significant compared to other EDS subtypes (e.g., spondylo dysplastic, arthrochalasia, kyphoscoliotic, and classical-like type 2 EDS) [9, 43, 44, 48, 49, 52, 59, 64, 65, 68] or skeletal dysplasia [39], and suggests a potential involvement of skeletal fragility in determining a poorer quality of life (QoL) in adult patients. Our findings emphasize a milder phenotype and disease course in cEDS compared to hEDS [50, 69] and other EDS subtypes (e.g., cEDS type 1 and 2, kyphoscoliotic, spondylo dysplastic,
myopathic, and musculocontractural EDS) [9] also regarding muscular and neuropsychiatric involvement. Indeed, in our cohort, apart from myalgias and cramps that affected about 50% of adults, primary (causing delayed motor development and clumsiness in few cases) or acquired muscle hypotonia/weakness (always of mild degree), and involuntary muscle contractions were quite rare; fibromyalgia was only a sporadic observation. These muscular complications, except primary hypotonia, are instead very frequent in hEDS and they intensely contribute to the poor QoL in adulthood [50, 69], when patients usually show generalization and progressive chronicity of musculoskeletal pain, which is often diagnosed as fibromyalgia [79], summation of other forms of chronic pain, such as pelvic pain (in women) and migraine as well as exacerbation of fatigue, together with additional complaints including paresthesia, mixed functional gastrointestinal disorders, and orthostatic intolerance [71]. In our cEDS cohort, headache/migraine and chronic fatigue were referred respectively by ~41% and ~36% of cEDS patients, especially by adults even though not statistically significant, whereas impaired memory and concentration and paresthesia were both more recurrent in adults (~40% vs ~10%). Cardiovascular dysautonomia as well as allodynia and sleep disturbance were less frequent (~15%); 5 adults mentioned chronic pain needing opioid therapy, whereas neuropathic pain was present only in the most severely affected patient. While fatigue affects about 1/3 of the general population [80], the chronic fatigue syndrome, defined as fatigue lasting longer than 6 months, occurs only in ~1% of the general population [81, 82] and is usually associated with impaired memory, cognitive deficits, muscle and joint pain, headaches, non-restorative sleep, post-exertional illness as well as psychological issues [83–85]. The discreetly high incidence of chronic fatigue observed in our cEDS cohort is in line with previous observations that emphasized that in EDS this issue is more common than in the general population and likely contributes to the patients’ functional impairment, psychological distress, and decreased QoL [86–89]. Like in the general population, in cEDS fatigue is multifactorial with contributing factors including articular pain, headache, sleep disturbance, and abnormally low blood pressure often associated with postural orthostatic tachycardia syndrome (POTS) or neurally mediated hypotension (NMH), nutritional deficiency, medications, and/or allergies (present in 32% of our patients) [80, 81, 87, 90–95]. Cerebrospinal fluid leak, which has been reported in cEDS as a cause of postural hypotension and headache [96], was not diagnosed in our cohort (e.g. increase in headache following Valsalva maneuver or reduction of headache when the patient takes a prone position) and only few patients with persistent migraine were investigated by imaging techniques with negative results. The first evidence for a possible link between EDS and autonomic dysfunction was published by Rowe et al. [86], who studied eleven pediatric patients (cEDS and hEDS) all showing either POTS or NMH. The concept was later reinforced by further studies that demonstrated a significant increase of the rate of systemic dysautonomic symptoms in hEDS [31, 97]. In our cEDS cohort, cardiovascular dysautonomia, although not particularly frequent, can explain orthostatic intolerance, palpitations, and tachycardia as well as some neurological secondary manifestations including fatigue, mood swings, and memory and concentration troubles. Besides, it has been proposed that in EDS dysautonomia might contribute also to features affecting the gastrointestinal and urinary systems (e.g. gut dysmotility and underactive/overactive bladder) as well as to certain psychological traits [98, 99]. Indeed, psychological dysfunction and emotional problems (e.g. depression, anxiety, panic, fears, affective disorder, low self-confidence, negative thinking, and hopelessness) are common features among EDS patients [92, 100–105]. Some of these issues, which may worsen the pain experience as well as other organ system manifestations (gastrointestinal and autonomic), were encountered also in our cohort with anxiety, panic, and/or fears that were referred by ~15% of patients. Chronic depression requiring pharmacological treatment was instead rare.

Concerning gastrointestinal involvement, its relevance in EDS and other HCTDs is well recognized [31, 69], whereas, until now, these issues were only slightly investigated in cEDS [106]. A previous study, which intended to explore the relationship between hEDS or gJHM with gastrointestinal disorders, showed that treatment-resistant functional issues such as gastroesophageal reflux, dysphagia, heartburn, swelling, constipation, recurrent abdominal pain, and irritable bowel syndrome, might be observed in 1/3 to 3/4 of patients with an increasing rate by age [107]. In our cEDS cohort, the most common feature was gastroesophageal reflux, especially in adults (~52% vs ~22%); however, unlike hEDS, it was mostly responsive to treatment with proton pump inhibitors and/or nizatidine. Constipation with or without other features of voiding dysfunction was often the initial sign of gastrointestinal involvement, but problems such as hemorrhoids, rectal bleeding, and anal fissures were uncommon and more serious complications such as rectal prolapse or fecal impaction did not occur. Likewise, hiatal hernia, visceroptosis, dolichocolon, and celiac disease, for which increased rates were described in hEDS [108, 109], were only sporadic observations in our sample.

In females with EDS, gynecologic complaints, such as mucosal problems with their genital area [69], heavy menstrual or intermenstrual bleedings [110] and painful intercourse [71, 111] are commonly encountered with
an incidence ranging from 30 to 75%. The frequencies of disabling dysmenorrhea (~23%) and meno/metrorrhagias (~16%) observed in our cohort are basically in line with these previous observations, but the high incidence of these issues also in the general population does not allow to draw relevant conclusions. Pelvic floor disorders including urinary stress incontinence, pelvic organ prolapse, and other sensory and emptying abnormalities were very uncommon among our affected females. As in the general population, childbirth has a very substantial impact on a woman’s probability of these complaints. Several case-control studies in the past suggested that EDS is associated with pelvic floor disorders [111–113], but most of these studies have not controlled for childbirth history or age and included patients affected by various types of EDS. Furthermore, several additional pregnancy-related complications have been more commonly reported in women with EDS in some studies [114] but as often, not validated in others [110, 115, 116]. Particularly for cEDS, it was suggested that pregnancy places both the newborn and the mother at risk for complications, which are assumed to be more frequent than in the normal population [16]. However, no comprehensive studies exist, and it is therefore very difficult to quantitate the incidence and related risk of each complication in affected individuals. In our cohort, most women had uncomplicated pregnancies (even multiple), deliveries, and postpartum period. Indeed, miscarriages, premature rupture of membranes, preterm birth, vaginal laceration during delivery, and post-partum uterine hemorrhage were rare or sporadic as well as rectal and urethral prolapse that occurred only in the most severely affected individual. Uterine rupture in the last trimester of pregnancy, which is particularly significant in vEDS as it associates with a high mortality rate (~5%) in affected females [46, 117, 118], did never happen in our patients. Overall, though the small sample size, pregnancy-associated complications seem to be unusual in cEDS. Accurate monitoring of women throughout gestation and in the postpartum period is still recommended, also considering that pregnancy was one of the most important sources of anxiety in our cEDS females.

The vascular aspect of EDS in general remains the major fear for the patients and their clinicians, especially regarding the possibility of arterial aneurysms, dissections and ruptures of medium-sized and large arteries. These life-threatening complications are principally the hallmark of vEDS together with gastrointestinal and uterine fragility, but they may occur also in other EDS subtypes, including rare individuals with a severe form of cEDS [16]. However, an exact estimation of prevalence and risk of these vascular complaints and possible genotype-phenotype correlations in cEDS are still missing [16, 119]. In particular, either the specific c.934C>T, p.(Arg312Cys) variant in COL1A1 or COL5A1 variants causing glycine substitutions at the C-terminal end of the triple helix domain have been associated with propensity to severe arterial events in early adulthood, but these assumptions are still a matter of debate due to the limited number of reports [10–14, 22, 25]. In our cEDS cohort, easy bruising, which is present to a variable degree in all EDS subtypes, was the most common finding (~87%). A bleeding tendency, despite normal coagulation status, manifesting either as meno/metrorrhagia and (lesser frequently) postnatal or peri-operative hemorrhage or as gingival bleeding/recurrent epistaxis (~41%) were also common. Varicose veins (~20%) and Raynaud’s phenomenon/acrocyanosis/livedo reticularis (~11%) were relatively unusual. All these features, except varicose veins, did not display any sex and age bias. MVP showed instead a significantly higher incidence in adults (~56% vs ~22%). Nevertheless, MVP was utmost without or of little clinical consequence, valvular regurgitation with mild hemodynamic involvement was rare (~35%), and none of our patients required surgical intervention, in line with earlier reports [16, 20]. Similarly, non-progressive aortic root dilatation was infrequent (~9%) as well as aortic ectasias (only 2 adult males) and tricuspid valve prolapse and bicuspid aortic valves were sporadic findings, thus suggesting that regular routine echocardiograms to assess for valvular diseases and aortic root dilatation may not be strictly necessary unless warranted by presence of symptoms or family history. MVP was formerly considered a common feature of all EDS subtypes and many other HCTDs, but that happened prior to the establishment of the more rigorous criteria for the diagnosis of MVP. Since then, some studies showed no significant increase in the incidence of MVP in EDS compared to the general population [18–20], whereas others disclosed a higher MVP frequency (28–67%) [120, 121, 122]. Considering the rate of MVP observed in our cEDS cohort and the knowledge that the mitral valve depends upon collagen for its tensile strength and that myxomatous MVP is characterized by disruption of the collagen layer with expansion of glycosaminoglycans within the middle layer of the valve [123], it is reasonable to consider MVP as a potential clue for cEDS, although the true clinical significance is so far unknown. The most noteworthy vascular complaints in our cohort were two aortic ectasias, an arteriovenous fistula, an interatrial septal aneurysm and an intracrural aneurysm; all these issues, except one of the two z scores >2, were recognized in adults harboring a COL5A1 null allele. Spontaneous rupture of large arteries was not observed at all and, in particular, neither in the 6 patients with the COLIA1 p.(Arg312Cys) missense variant nor in 2 individuals with different COL5A1 glycine substitutions at the C-terminal domain (Additional
Table 1), which represent variants previously associated with a possible higher risk of vascular events [16]. The fact that i) these 8 patients were originally diagnosed major vascular events (1 individual with the COLIA1 variant showed aortic ectasia, uncomplicated tortuous vertebral arteries, and left ventricular thickening), and ii) all underwent periodical vascular surveillance that resulted negative at the time of writing, suggests that the supposed genotype-phenotype correlations of these variants should not be considered valid in all cases. The finding that major vascular complaints and/or rupture can be rarely recognized also in patients with different COL5A1 variants [5, 21, 23, 24, 26] advises that a cerebral, thoracic, and abdominal MRI at diagnosis might be considered in a precautionary way for all adult cEDS patients. Once significant changes in arterial caliber are not detected and in pediatric patients, a doppler-ultrasound of supra-aortic branches and abdominal arteries, and a heart doppler-ultrasound with aortic root, arch, and ascending aorta evaluation every 4–5 years might be enough together with cardiovascular risk factors monitoring. Overall, despite the few above-mentioned reports and the suggestion for a possible association between type V collagen defects and cardiovascular fragility demonstrated in Col5a1 and Col5a2 knock-out mice [124, 125], our results suggest that the risk for severe vascular complications seems to be fairly low in humans harboring a type V collagen defect and the presence of additional, yet unknown, genetic modifiers in families with a severe vascular phenotype is reasonable.

Conclusions
In conclusion, we explored the accuracy of the 2017 nosology for the cEDS diagnosis in a cohort of patients from different ages and sexes with a defined molecular defect and tried to offer a full picture of the multisystemic involvement and some views on the natural history of this condition. Our findings define the value of atrophic scars, skin hyperextensibility, JHM and its complications in selecting patients for molecular testing and the relevance of the additional clinical signs associated with cEDS, which should contribute to the rapid ascertainment of cEDS patients and facilitate differential diagnosis. Promptly recognizing among the different EDS subtypes and confirmatory genetic testing is indeed increasingly important as these disorders are characterized by different natural histories and prognoses. Moreover, our results suggest the need of a future update of the currently defined diagnostic criteria for cEDS. Additional studies on large cEDS cohorts are expected to confirm the limited multisystemic involvement and rather favorable natural history of cEDS and to explore possible genotype-phenotype correlations, which would permit to establish management guidelines.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13023-020-01470-0.

Additional file 1: Table 1. Clinical and molecular features of all cEDS patients.
Additional file 2: Table 2. Multisystemic features in the cEDS patients’ cohort by sex and age.

Abbreviations
BS: Brighton score; cEDS: Classical Ehlers-Danlos syndrome; cEDS: Classical-like Ehlers-Danlos syndrome; CTP: Connective tissue panel; EDS: Ehlers-Danlos syndrome; gJHM: Generalized joint hypermobility; HCTD: Heritable connective tissue disorder; hEDS: Hypermobile Ehlers-Danlos syndrome; JHM: Joint hypermobility; LOVD: Leiden Open Variation Database; MLPA: Multiplex ligation-dependent probe amplification; MRI: Magnetic resonance imaging; MVP: Mitral valve prolapse; NGS: Next generation sequencing; NMH: Neuromediated hypotension; POTS: Postural orthostatic tachycardia syndrome; QoL: Quality of life; SD: Standard deviation; vEDS: Vascular Ehlers-Danlos syndrome

Acknowledgements
The authors wish to thank the patients and their families for the cooperation during the diagnostic process and participation in this study and the Fazzo Cusan family for its generous support.

Authors’ contributions
MC and MR conceived the study and coordinated the clinical study to collect the clinical data and assessed the obtained clinical findings. MR and MC drafted the manuscript with substantial support by VC and NC, who organized data contents, reviewed the literature, completed figures and tables and prepared the additional files. Patients were clinically evaluated and recruited with informed consent by MC and MV. The molecular genetic studies, sequence alignments, and annotations of identified sequence alterations were performed by MR, VC, and NC. All authors discussed, read and approved the final manuscript.

Funding
Not applicable. No funding was active on this project.

Availability of data and materials
All data generated or analyzed during this study are included in this published article and its Additional files.

Ethics approval and consent to participate
This study was carried out according to the Declaration of Helsinki principles and approved by the local Ethical Committee (Comitato Etico di Brescia, ASST degli Spedali Civili, Brescia, Italy, registration number NP3873). Molecular testing was achieved in the genetic laboratory at the Department of Molecular and Translational Medicine of the University of Brescia in compliance with the Italian legislation on genetic diagnostic tests. The patients (or their parents) signed informed consent for molecular analysis, participation to the study and publication of clinical photographs.

Consent for publication
Written consent for publication of clinical data was obtained from all participants (or their parents).

Competing interests
All authors declare that they have no competing interest concerning this work.

Author details
1Division of Biology and Genetics, Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, I-25123 Brescia, Italy.
References

1. Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Hum Genet Part C Semin Med Genet. 2017;1758–26.

2. Schwazze U, Atkinson M, Hoffman GG, Greenspan DS, Byers PH. Null alleles of the COL5A1 gene of type V collagen are a cause of the classical forms of Ehlers-Danlos syndrome (types I and II). Am J Hum Genet. 2000;66:1757–65.

3. Wenstrup RJ, Florer JB, Willing MC, Giunta C, Steinmann B, Young F, et al. The Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Am J Hum Genet. 2000;66:1766–76.

4. Malfait F, Coucke P, Symoens S, Loeyts B, Nuytinck L, De Paepe A. The molecular basis of classical Ehlers-Danlos syndrome: a comprehensive study of biochemical and molecular findings in 48 unrelated patients. Hum Mutat. 2005;25:28–37.

5. Symoens S, Syx D, Malfait F, Callewaert B, De Backer J, Vanacker O, et al. Comprehensive molecular analysis demonstrates type V collagen mutations in over 90% of patients with classic EDS and allows to refine diagnostic criteria. Hum Mutat. 2012;33:1485–93.

6. Ritelli M, Dordoni C, Venturini M, Chiarelli N, et al. Clinical and molecular characterization of 40 patients with classical Ehlers-Danlos syndrome: identification of 18 COL5A1 and 2 COL5A2 novel mutations. Orphanet J Rare Dis. 2013;8.

7. Colombi M, Dordoni C, Venturini M, Ciaccio C, Morlino S, Chiarelli N, et al. Spectrum of mucocutaneous, ocular and facial features and delineation of novel presentations in 62 classical Ehlers-Danlos syndrome patients. Clin Genet. 2017;92:624–31.

8. Colombi M, Dordoni C, Cinquina V, Venturini M, Ritelli M. A classical Ehlers-Danlos syndrome family with incomplete presentation diagnosed by whole exome sequencing. Genet Med. 2015;17:73–80.

9. Brady AF, Demiradas S, Fourmel-Gigleux S, Ghali N, Giunta C, Kapferer-Seebacher I, et al. The Ehlers-Danlos syndromes, rare types. Am J Med Genet Part C Semin Med Genet. 2017;175:70–115.

10. Nuytinck L, Freund M, Lagae L, Hermans GE, Haddad PR, et al. Null alleles of the COL5A1 gene of type V collagen are a cause of the classical forms of Ehlers-Danlos syndrome (types I and II). Am J Hum Genet. 2000;66:1757–65.

11. Leeuw K, Goorhuis J, Thijs BL, Symoens S, Malfait F, De Paepe A, et al. Superior mesenteric artery aneurysm in a 9-year-old boy with classical Ehlers-Danlos syndrome. Am J Med Genet Part A. 2012;158A:1626–9.

12. Mehta S, Dhar S, Bamba S. Common iliac artery aneurysm and spontaneous dissection with contralateral iatrogenic common iliac artery dissection in classic ehlers-danlos syndrome. Int J Angiol. 2012;21:167–9.

13. Arai A, Stoler JM. Ehlers-Danlos syndrome: an unusual presentation you need to know about. Case Rep Pediatr. 2013;2013:1–5.

14. Monroe GR, Harakalova M, van der Crabben SN, Bontoli-Avellana AM, Moll FL, et al. Familial Ehlers-Danlos syndrome with lethal arterial events caused by a mutation in COL5A1. Am J Med Genet Part A. 2015;167:1196–203.

15. Yasuda S, Imoto K, Uchida K, Machida D, Yanagi H, Sugita T, et al. Successful endovascular treatment of a ruptured superior mesenteric artery in a patient with Ehlers-Danlos syndrome. Ann Vasc Surg. 2013;27:975.e1–5.

16. Dalglish R. The human collagen mutation database. 1998. Nucleic Acids Res. 1998;26:253–5.

17. Colombi M, Dordoni C, Chiarelli N, Ritelli M. Differential diagnosis and diagnostic flow chart of joint hypermobility syndrome/ehlers-danlos syndrome hypermobility type compared to other heritable connective tissue disorders. Am J Med Genet Part C Semin Med Genet. 2015;169:22–31.

18. Castori M, Dordoni C, Morlino S, Sperduti I, Ritelli M, Valiante M, et al. Spectrum of mucocutaneous manifestations in 277 patients with joint hypermobility syndrome/Ehlers-Danlos syndrome, hypermobility type. Am J Med Genet Part C Semin Med Genet. 2015;169:43–53.

19. Meester JAN, Verstraeten A, Schepens D, Alabert M, Van Laer L, Loeyts BL. Differences in manifestations of Marfan syndrome, Ehlers-Danlos syndrome, and Loeyts-Dietz syndrome. Ann Cardiothorac Surg. 2017;6:892–94.

20. Hakim AJ, Grahame R. A simple questionnaire to detect hypermobility: an adjunct to the assessment of patients with diffuse musculoskeletal pain. Int J Clin Pract. 2003;57:163–6.

21. Ritelli M, Morlino S, Giacopuzzi E, Corini G, Cinquina V, Chiarelli N, et al. Ehlers-Danlos syndrome with lethal cardiac valvular dystrophy in males carrying a novel splice mutation in FBN1. Am J Med Genet Part A. 2017;173:169–76.

22. Ritelli M, Chiarelli N, Dordoni C, Riffo E, Venturini M, Quirini S, et al. Arterial tortuosity syndrome: homozygosity for two novel and one recurrent SLCA10 missense mutations in three families with severe cardiopulmonary complications in infancy and a literature review. BMC Med Genet. 2014;15:122.

23. Castori M, Ritelli M, Zoppi N, Molisso L, Chiarelli N, Zaccagna F, et al. Adult presentation of arterial tortuosity syndrome in a 51-year-old woman with a novel homozygous c.1411+1G>A mutation in the SLCA10 gene. Am J Med Genet Part A. 2012;158A:1164–9.

24. Morlino S, Micali L, Ritelli M, Rohrbach M, Zoppi N, Vandersteen A, et al. COL1A1-related overlap disorder: a novel connective tissue disorder incorporating the osteogenesis imperfecta/Ehlers-Danlos syndrome overlap. Clin Genet. 2020;97:396–406.

25. Dietz H. Marfan syndrome. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews®. Seattle (WA): University of Washington, Seattle; 2020. [updated 2017 Oct 12].

26. Loeyts BL, Dietz HC. Loeyts-Dietz syndrome. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews®. Seattle (WA): University of Washington, Seattle; 2020. [updated 2018 mar 1].

27. De Paepe A, Coucke P, Aruffo A. Arterial tortuosity syndrome. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews®. Seattle (WA): University of Washington, Seattle; 2008. p. 1993–1996. [updated 2017 Oct 12].

28. Callewaert B, De Paepe A, Coucke P. Arterial tortuosity syndrome. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews®. Seattle (WA): University of Washington, Seattle; 2014. p. 1993–2002. [updated 2014 Dec 18].

29. Legrand A. Classical Ehlers-Danlos syndrome with a propensity to arterial events: a new report on a French family with a COL1A1 p.Arg312Cys variant. Clin Genet. 2020;97:357–61.

30. Beighton P, De Paepe A, Steinmann B, Tijdens P, Wenstrup RJ. Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Am J Hum Genet. 1998;63:371–37.

31. Bowen JM, Sobey GI, Burrows NP, Colombi M, Lavallee ME, Malfait F, et al. Ehlers-Danlos syndrome, classical type. Am J Med Genet Part C Semin Med Genet. 2017;175:27–39.

32. Remvig L, Duhn PH, Ullman S, Kobayasi T, Hansen B, Juulkristensen B, et al. Skin extensibility and consistency in patients with Ehlers-Danlos syndrome and benign joint hypermobility syndrome. Scand J Rheumatol. 2009;38:227–30.

33. Wenstrup RJ, Meyer RA, Lyle JS, Hoechstetter L, Rose PS, Levy HP, et al. Prevalence of aortic root dilation in the Ehlers-Danlos syndrome. Genet Med. 2002;4:112–7.
41. Ritelli M, Morlino S, Giacopuzzi E, Bernardini L, Torres B, Santoro G, et al. A recognizable systemic connective tissue disorder with polyvalvar heart dystrophy and dysmorphism associated with TAB2 mutations. Clin Genet. 2018;93:126–33.

42. Morlino S, Castori M, Dordoni C, Cinquina V, Santoro G, Grammatico P, et al. A novel MAPK13 splice mutation causes cardiopulmonary hypertension with features of hereditary connective tissue disorder. Eur J Hum Genet. 2018;26:582–6.

43. Ritelli M, Cinquina V, Venturini M, Pezzaioli L, Formenti AM, Chiarelli N, et al. Expanding the clinical and mutational spectrum of recessive AEBP1-related classical-like Ehlers-Danlos syndrome. Genes (Basel). 2019;10:135.

44. Ritelli M, Cinquina V, Giacopuzzi E, Venturini M, Chiarelli N, Colombi M. Further defining the phenotypic spectrum of B3GAT3 mutations and literature review on linkeroaphy syndromes. Genes (Basel). 2019;10:831.

45. Ryden D, Ritelli M, Zoppì N, Cinquina V, Giunta C, Rohrbach M, et al. Clinical and molecular characterization of classical-like Ehlers-Danlos syndrome due to a novel TNXB variant. Genes (Basel). 2019;10:843.

46. Ritelli M, Rovati C, Venturini M, Chiarelli N, Cinquina V, Castori M, et al. Application of the 2017 criteria for vascular Ehlers-Danlos syndrome in 50 patients ascertained according to the Villefranche nomenclature. Clin Genet. 2020;97:287–95.

47. Steiner RD, Basel D. COL1A1/2 osteogenesis imperfecta. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews®. Seattle (WA): University of Washington, Seattle; 2005. p. 1993–2020. [Updated 2019 Dec. 12].

48. Ritelli M, Dordoni C, Cinquina V, Venturini M, Calzavara-Pinton P, Colombi M. Expanding the clinical and mutational spectrum of B4GALT7-spondylodyplastic Ehlers-Danlos syndrome. Orphanet J Rare Dis. 2017;12:153.

49. Caraffi SG, Maini I, Ivanovski I, Pollazzon M, Giangiobbe S, Valli M, et al. A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency. N Engl J Med. 2001;345:1167–73.

50. Castori M, Tinkle B, Levy H, Grahame R, Malfait F, Hakim A. A framework for the classification of joint hypermobility and related conditions. Am J Med Genet Part C Semin Med Genet. 2017;157:148–57.

51. Schalkwijk J, Zweers MC, Steijlen PM, Dean WB, Taylor G, Van Vlijmen IM, et al. Recognizing the tenascin-X deficient type of Ehlers-Danlos syndrome. Genet Med. 2016:882–91.

52. Zweers MC, Dean WB, Pagon RA, et al., editors. GeneReviews®. Seattle (WA): University of Washington, Seattle; 2005. p. 1993–2020. [Updated 2018 Oct 18].

53. Guanta C, Rohrbach M, Fauth C, et al. FKB14-spondylodyplastic Ehlers-Danlos syndrome. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews®. Seattle (WA): University of Washington, Seattle; 2019. p. 1993–2020.

54. Klaassen M, Reinstein E, Hilhorst-Hoefste Y, Schrandt JJP, Malfait F, Staal H, et al. Ehlers-Danlos arthrochasia type (VIA-B) - expanding the phenotype: from prenatal life through adulthood. Clin Genet. 2012;82:121–30.

55. Aoyub S, Ghali N, Angwin C, Baker D, Baffini S, Brady AF, et al. Clinical features, molecular results, and management of 12 individuals with the rare arthrochasia Ehlers-Danlos syndrome. Am J Med Genet Part A. 2020;182(2):994–1007.

56. Tinkle B, Castori M, Berglund B, Cohen H, Grahame R, Kaczak H, et al. Hypermobile Ehlers–Danlos syndrome (aka. Ehlers–Danlos syndrome type III and Ehlers–Danlos syndrome hypermobility type): clinical description and natural history. Am J Med Genet Part C Semin Med Genet. 2017;175:48–69.

57. Castori M, Dordoni C, Valiante M, Sperduti I, Ritelli M, Morlino S, et al. Nosology and inheritance pattern(s) of joint hypermobility syndrome and Ehlers-Danlos syndrome, hypermobility type: a study of intrafamilial and interfamilial variability in 23 Italian pedigrees. Am J Med Genet Part A. 2014;164:3010–20.

58. Castori M, Camerota F, Celletti C, Grammatico P, Padua L. Ehlers-Danlos syndrome hypermobility type and the excess of affected females: possible mechanisms and perspectives. Am J Med Genet A. 2010;152A:406–8.

59. Castori M, Morlino S, Celletti C, Cibelliini G, Bruschiini M, Grammatico P, et al. Re-writing the natural history of pain and related symptoms in the joint hypermobility syndrome/Ehlers-Danlos syndrome, hypermobility type. Am J Med Genet A. 2013;161:2989–3004.

60. Morlino S, Dordoni C, Sperduti I, Venturini M, Celletti C, Camera F, et al. Refining patterns of joint hypermobility, habitus, and orthopedic traits in joint hypermobility syndrome and Ehlers-Danlos syndrome, hypermobility type. Am J Med Genet Part C Semin Med Genet. 2017;173:594–605.

61. Deadhar AA, Woof AD. Ehlers Danlos syndrome and osteoporosis. Ann Rheum Dis. 1994;53:841–2.

62. Dolan AL, Arden NK, Grahame R, Spector TD. Assessment of bone in Ehlers-Danlos syndrome. Rheum Dis. 1994;53:841–7.

63. Morlino S, Dordoni C, Sperduti I, Venturini M, Celletti C, Camera F, et al. High prevalence of radiological vertebral fractures in adult patients with Ehlers-Danlos syndrome. Bone. 2016;84:88–93.

64. Basalom S, Rauch F. Bone Disease in Patients with Ehlers-Danlos Syndrome. Curr Osteoporos Rep. 2020;18:95-102.

65. Yeowell HH, Steinmann B. PLOD1-related Kyphoscoliotic Ehlers-Danlos syndrome. Orphanet J Rare Dis. 2020(2020) 15:197.

66. Formenti AM, Doga M, Frara S, Ritelli M, Colombi M, Banfi G, et al. Skeletal features, molecular results, and management of 12 individuals with the rare arthrochasia Ehlers-Danlos syndrome. Orphanet J Rare Dis. 2020;15:197.

67. Dolan AL, Arden NK, Grahame R, Spector TD. Assessment of bone in Ehlers-Danlos syndrome. Rheum Dis. 1994;53:841–7.

68. Formenti AM, Doga M, Frara S, Ritelli M, Colombi M, Banfi G, et al. Skeletal features, molecular results, and management of 12 individuals with the rare arthrochasia Ehlers-Danlos syndrome. Orphanet J Rare Dis. 2020;15:197.

69. Formenti AM, Doga M, Frara S, Ritelli M, Colombi M, Banfi G, et al. Skeletal fragility: an emerging complication of Ehlers–Danlos syndrome. Endocrine. 2019;63:225–30.

70. Mazziotti G, Dordoni C, Doga M, Galderisi F, Venturini M, Calzavara-Pinton P, et al. High prevalence of radiological vertebral fractures in adult patients with Ehlers-Danlos syndrome. Bone. 2016;84:88–92.

71. Basalom S, Rauch F. Bone Disease in Patients with Ehlers-Danlos Syndrome. Curr Osteoporos Rep. 2020;18:95-102.

72. Ting TV, Hashkiri PJ, Schiller K, Desai AM, Spalding S, Hashkari-Zuck S. The role of benign joint hypermobility in the pain experience in juvenile fibromyalgia: an observational study. Pediatr Rheumatol. 2012;10:16.

73. Kizilbash SJ, Ahrens SP, Bruce BK, Chelmissky G, Discolll SW, Harbeck-Weber C, et al. Adolescent fatigue, POTS, and recovery: a guide for clinicians. Curr Probl Pediatr Adolesc Health Care. 2014;44:108–33.

74. Wierer CL, Nijhoff SL, Van De Putte EM. Clinical practice: chronic fatigue syndrome. Eur J Pediatr. 2013;172:1293–300.

75. Clayton EW. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: an IOM report on redefining an illness. JAMA. 2015;313:1101–2.

76. Forsey M, Libman E, Bailes S, Baltzan M, Schondorf R, Amel R, et al. Sleep quality and psychological adjustment in chronic fatigue syndrome. J Behav Med. 2004;27:581–605.
70. Nijs J, Meeus M, De Meirleir K. Chronic musculoskeletal pain in chronic fatigue syndrome: recent developments and therapeutic implications. Man Ther. 2006;11:187–91.

71. Meeus M, Nijs J, De Meirleir K. Chronic musculoskeletal pain in patients with the chronic fatigue syndrome: a systematic review. Eur J Pain. 2007;11:377–86.

72. Rowe PC, Barron DF, Calkins H, Maumenee IH, Tong PY, Geraghty MT. Orthostatic intolerance and chronic fatigue syndrome associated with Ehlers-Danlos syndrome. J Pediatr. 1999;135:494–9.

73. Voermans NC, Knoop H, van de Kamp N, Hamel BC, Bleijenberg G, van Engelen BG. Fatigue is a frequent and clinically relevant problem in Ehlers-Danlos syndrome. Semin Arthritis Rheum. 2010;40:267–74.

74. Rombaut L, Schepers M, De Wande I, De Vries J, Meeus M, Malfait F, et al. Chronic pain in patients with the hypermobility type of Ehlers-Danlos syndrome: evidence for generalized hyperalgesia. Clin Rheumatol. 2015;34:1121–9.

75. Castori M, Sperduti ICC. Symptom and joint mobility progression in the joint hypermobility syndrome. Clinique Phlebologique. 2011;29(6):998–105.

76. Kanjwal K, Saeed B, Majewski P, Faghfoury H, et al. Dysautonomia and its underlying mechanisms in the hypermobility type of Ehlers-Danlos syndrome (EDS) focusing on oral symptoms: a questionnaire study. Orthod Craniofacial Res. 2004;7:178–85.

77. De Wande I, Rombaut L, Leybaert L, Van de Borne P, De Backer T, Malfait F, et al. Dysautonomia and its underlying mechanisms in the hypermobility type of Ehlers-Danlos syndrome. Semin Arthritis Rheum. 2014;44(9):102–9.

78. Farmer AD, Fikree A, Aziz Q. Addressing the confounding role of joint hypermobility syndrome and gastrointestinal involvement in postural orthostatic tachycardia syndrome. Clin Auton Res. 2014;24:157–8.

79. Eccles JA, Owens AP, Mathias CJ, Umeda S, Critchley HD. Neurovisceral phenotypes in the expression of psychiatric symptoms. Front Neurosci. 2015;9:54.

80. Hagberg C, Korpel A, Andersson-Norinder J, Berglund B. Ehlers-Danlos syndrome (EDS) focusing on oral symptoms: a questionnaire study. Orthod Craniofacial Res. 2004;7:178–85.

81. Castori M, Camerota F, Celletti C, Danese C, Santilli V, Saraceni VM, et al. Natural history and manifestations of the hypermobility type Ehlers-Danlos syndrome: a pilot study on 21 patients. Am J Med Genet Part B Neuropsychiatr Genet. 2019;180:25–4.

82. Gaisl T, Giunta C, Bradton DJ, Sutherland K, Schlatter C, Sevi N, et al. Obstructive sleep apnoea and quality of life in Ehlers-Danlos syndrome: a parallel cohort study. Thorax. 2017;72:729–35.

83. Stolber AS, Gaisl T, Giunta C, Sevi NA, Singer F, Möller A, et al. Obstructive sleep Apnoea in children and adolescents with Ehlers-Danlos syndrome. Respiration. 2019;97:284–91.

84. Scheinvin WL, Gordon OK, Tout J. Connective tissue disorders with spontaneous cerebral spinal fluid leaks and intracranial hypotension: a prospective study. Neurosurgery. 2004;54:65–70.

85. De Wande I, Rombaut L, Leybaert L, Van de Borne P, De Backer T, Malfait F, et al. Dysautonomia and its underlying mechanisms in the hypermobility type of Ehlers-Danlos syndrome. Semin Arthritis Rheum. 2014;44(9):102–9.

86. Farmer AD, Fikree A, Aziz Q. Addressing the confounding role of joint hypermobility syndrome and gastrointestinal involvement in postural orthostatic tachycardia syndrome. Clin Auton Res. 2014;24:157–8.

87. Eccles JA, Owens AP, Mathias CJ, Umeda S, Critchley HD. Neurovisceral phenotypes in the expression of psychiatric symptoms. Front Neurosci. 2015;9:54.

88. Haggberg C, Karpe L, Andersson-Norinder J, Berglund B. Ehlers-Danlos syndrome and gastrointestinal manifestations: a 20-year experience at Mayo Clinic. Neurogastroenterol Motil. 2015;27:1657–66.

89. Castori M, Morlino S, Pascolini G, Blundo C, Grammatico P. Gastrointestinal and nutritional issues in joint hypermobility syndrome/ehlers-danlos syndrome, hypermobility type. Am J Med Genet Part C Semin Med Genet. 2015;169:54–75.

90. Danese C, Castori M, Celletti C, Amato S, Lo Russo C, Grammatico P, et al. Screening for celiac disease in the joint hypermobility syndrome/ Ehlers-Danlos syndrome hypermobility type. Am J Med Genet A. 2011; 153:2314–6.

91. Laszkowska M, Roy A, Lebwohl B, Green PHR, Sundelin HEK, Ludvigsson JF. Nationwide population-based cohort study of celiac disease and risk of Ehlers-Danlos syndrome and joint hypermobility syndrome. Dig Liver Dis. 2016;48:1030–4.

92. Horton J, Lebègue G, Becourt S, Hamonnet C, Gompel A. Gynecologic symptoms and the influence on reproductive life in 386 women with hypermobility type ehlers-danlos syndrome: a cohort study. Orphanet J Rare Dis. 2016;11:124.

93. Norton PA, Baker JE, Sharp HC, Warensec JS. Genitourinary prolapse and joint hypermobility in women. Obstet Gynecol. 1995;85:225–8.

94. Mc Intosh LS, Stantiff DF, Mallett VT, Frahm JD, Richardson DA, Evans ML. Ehlers-danlos syndrome: relationship between joint hypermobility, urinary incontinence, and pelvic floor prolapse. Gynecol Obstet Invest. 1996;44:135–9.

95. Aydeniz A, Dikensoy E, Cebesoy B, Atalmaq O, Cürşoy S, Balat O. The relation between genitourinary prolapse and joint hypermobility in Turkish women. Arch Gynecol Obstet. 2010;281:301–4.

96. Hurst BS, Lange SJS, Kullstam SM, Usadi RS, Matthews ML, Marshburn PB, et al. Obstetric and gynecologic challenges in women with ehlers-danlos syndrome. Obstet Gynecol. 2014;123:506–13.

97. Castori M, Morlino S, Dordoni C, Celletti C, Camerota F, Ritelli M, et al. Gynecologic and obstetric implications of the joint hypermobility syndrome (a.k.a. Ehlers-Danlos syndrome hypermobility type) in 82 Italian patients. Am J Med Genet Part A. 2012;158 A:2176–82.

98. Sundelin HEK, Stephansson O, Johansson K, Ludvigsson JF. Pregnancy outcome in joint hypermobility syndrome and Ehlers-Danlos syndrome. Acta Obstet Gynecol Scand. 2017;96(6):114–9.

99. Germain DP, Herrera-Guzman Y. Vascular Ehlers-Danlos syndrome. Ann Genet. 2004;47:1–9.

100. Murray ML, Pepin M, Peterson S, Byers PH. Pregnancy-related deaths and complications in women with vascular Ehlers-Danlos syndrome. Genet Med. 2014;16:874–80.

101. Malfait F. Vascular aspects of the Ehlers-Danlos syndromes. Matrix Biol. 2018;71–72:380–95.

102. Camerota F, Castori M, Celletti C, Colotto M, Amato S, Collella A, et al. Heart rate, conduction and ultrasound abnormalities in adults with joint hypermobility syndrome/Ehlers-Danlos syndrome, hypermobility type. Clin Rheumatol. 2014;33:981–7.

103. Kozanoglu E, Benlidayal IC, Akli RE, Tasal A. Is there any link between joint hypermobility and mitral valve prolapse in patients with fibromyalgia syndrome? Clin Rheumatol. 2016;35:1041–4.

104. Asher SB, Chen R, Killish S. Mitral valve prolapse and aortic root dilatation in adults with hypermobile Ehlers-Danlos syndrome and related disorders. Am J Med Genet Part A. 2018;176:1838–44.

105. Delling FN, Vasan RS. Epidemiology and pathophysiology of mitral valve prolapse: New insights into disease progression, genetics, and molecular basis. Circulation. 2014;129:2158–70.

106. Park AC, Phillips CL, Pfeiffer FM, Roenneburg DA, Kemien JF, Adams SM, et al. Homozygosity and Heterozygosity for Null Col5a2 Alleles Produce Embryonic Lethality and a Novel Classic Ehlers-Danlos Syndrome-Related Phenotype. Am J Pathol. 2015;187:2000–11.

107. Wenstrup RJ, Floerl JB, Davidson JM, Phillips CL, Pfeiffer BJ, Menezez DW, et al. Murine model of the Ehlers-Danlos syndrome: col5a1 haploinsufficiency disrupts collagen fibril assembly at multiple stages. J Biol Chem. 2006;281:12888–95.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.